Net clinical benefit of a reduced dose of DOACs in non-valvular atrial fibrillation: a meta-analysis of randomized trials.
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacological research"
DOI: 10.1016/j.phrs.2021.105902
Abstract: BACKGROUND In standard dosing, direct Oral Anticoagulants (DOACs) are used as an alternative to warfarin to prevent ischemic stroke and systemic embolism in non-valvular Atrial Fibrillation (AF). However, randomized comprehensive evidence considering the efficacy and… read more here.
Keywords: clinical benefit; benefit; net clinical; randomized trials ... See more keywords
COMPARISON OF EFFECTIVENESS, SAFETY, AND THE NET CLINICAL OUTCOME BETWEEN DIFFERENT DIRECT ORAL ANTICOAGULANTS IN 162,707 NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED IN US CLINICAL PRACTICE
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)30816-7
Abstract: Most observational studies on direct oral anticoagulants (DOACs) used single data sources with limited generalizability. This ARISTOPHANES (Anticoagulants for Reduction In STroke: Observational Pooled analysis on Health outcomes ANd Experience of patientS) study aimed to… read more here.
Keywords: effectiveness safety; oral anticoagulants; net clinical; comparison effectiveness ... See more keywords
Net‐clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14600
Abstract: Extended‐duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess the risk‐benefit of betrixaban… read more here.
Keywords: benefit; net clinical; venous thromboembolism; patients aged ... See more keywords
Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics?
Sign Up to like & getrecommendations! Published in 2018 at "Circulation"
DOI: 10.1161/circulationaha.117.033442
Abstract: The evaluation of novel antithrombotics requires a careful assessment of both efficacy and safety. Assessment of efficacy typically relies on a composite of cardiovascular death, myocardial infarction, and stroke (major adverse cardiac events) that are… read more here.
Keywords: clinical benefit; net clinical; benefit net; benefit testing ... See more keywords